New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Whole Foods Market Becomes Los Angeles' Largest Retailer and Nation's Largest Food Retailer Utilizing Solar Power Lighting System

LOS ANGELES--(BUSINESS WIRE)--Nov. 13, 2002--Whole Foods Market(R), Inc. (Nasdaq:WFMI), the world's largest natural and organic supermarket, and the Los Angeles Department of Water and Power (LADWP), the nation's largest municipally owned utility, have teamed up to create an on-site solar electric power co-generation system.

Under the management of California Associated Power, Inc, the system was recently installed at the Whole Foods Market store in Woodland Hills, Calif., making the company Los Angeles' largest major retailer and nation's largest food retailer to introduce solar energy as 25% of its power source. The official "solarbration" ceremony will take place at the store, 21347 Ventura Blvd. in Woodland Hills, and is scheduled for 10 a.m. on November 18, 2002; the public is invited to attend.

Under the LADWP's Solar Incentive Program, which provided more than $582,000 in incentives, Whole Foods Market brought together California Associated Power, Sunny Boy, Shell Solar (formerly Siemens Solar), The Gas Company and Sempra Energy to create a 108kW solar electric system to power the Woodland Hills store. The solar array, composed of Shell Solar(R) panels covering 18,000 square feet on the store's roof, turns the sun's free energy into usable power. These solar panels are electrically interconnected to Sunny Boy(TM) power modules, which feed high quality DC power to the store's existing electrical system and the utility grid at large. This innovative solar electric and lighting system maximizes the usable solar energy produced by the photovoltaic panels and increases the efficiency of power conversion.

"We are a company actively looking for ways to help preserve our planet's natural resources, and natural solar powered lighting systems made sense both from an economic and an environmental standpoint," said Michael Besancon, Southern Pacific regional president of Whole Foods Market. "Most importantly, this initiative is helping us to further our corporate mission of preserving the environment by promoting clean energy. We are planning to implement this technology with other stores throughout the Southern Pacific region."

"I'm pleased that this highly-regarded retailer and the LADWP are partnering to craft a smart energy solution that makes sense for our community and the environment," noted David Wiggs, general manager, LADWP.

"The Solar Power for a Green LA program is just one of the Green LA initiatives," commented Angelina Galiteva, executive director of Green LA environmental affairs and new product development, LADWP. "The innovative Green LA efforts are aimed at implementing cutting edge environmental technologies while responding to customer needs."

System Benefits

Whole Foods Market's new solar electrical system is expected to create significant economic and environmental benefits. In addition to an attractive amortization period, the system will:

    --  Produce and save more than 3 million kilowatt hours over 20
        years

    --  Result in more than 2,000 tons of CO2 emissions avoided, the
        equivalent of removing 536 cars from the roadways

    --  Reduce the equivalent of more than 2,000 tons of coal being
        burned

    --  Reduce the equivalent of removing 540,000 lbs of greenhouse
        gases

Shell Solar(R) solar electric roof panels system was selected as the best solar electric technology application for Whole Foods Market's unused flat roof space. Shell Solar(R) is a patented, lightweight photovoltaic roofing assembly that delivers clean solar electricity to the building.

About Whole Foods Market

Founded in 1980 in Austin, Texas, Whole Foods Market is the world's largest natural and organic foods supermarket. In fiscal year 2001, the company had sales of $2.3 billion and currently has more than 139 stores in the United States and Canada. The Whole Foods Market motto, "Whole Foods, Whole People, Whole Planet"(TM) captures the company's mission to find success in customer satisfaction and wellness, employee excellence and happiness, enhanced shareholder value, community support, and environmental improvement. Whole Foods Market, Bread & Circus(R) and Harry's Farmers Market(R) are all registered trademarks owned by Whole Foods Market and its affiliates. The company employs more than 24,000 team members and has been ranked for five consecutive years as one of the "Top 100 Companies to Work for" in America by Fortune magazine.

About Los Angeles Department of Water and Power (LADWP) and Green LA

The Solar Power Program is one in a series of Green LA initiatives that also includes Green Power, Energy Efficiently, Electric Transportation, Tree Planting for Green LA, Cool Schools Tree Planting and Recycling.

Further information about the Solar Power Program or Green LA initiative can be received by logging onto www.GreenLA.com. LADWP customers can also received information by phoning 1-800-GreenLA.

The Los Angeles Department of Water and Power is celebrating its 100th year of providing water and energy services to residents and businesses within the 465-square mile city of Los Angeles service area.

Contact: Kim Hughes, LADWP, 213/367-4417 or 213/792-9599 (cell)

About Shell Solar

Shell Solar is one of the world's largest manufacturers of photovoltaics. The company has decades of experience on the design and installation of solar power systems. With the innovative and trend-setting two-megawatt trade center roof of 1997, Shell Solar set new international standards for the photovoltaics industry. The company belongs to the Shell Solar Group, which operates throughout the world and has its headquarters in Amsterdam. Shell Solar has cutting-edge research, development and production facilities throughout the world. Shell Solar employs about 1,100 people and has partners for its products in over 90 countries. For more information, please visit their website, www.shell.com/solar.

Contact: Tina Nickerson, [email protected]

Cancer-Fighting Tomato Tops America's 2002 Best in Biotech

Consumers select top five biotech advances of the year

WASHINGTON, Nov. 13 /PRNewswire/ -- The prospect of a cancer-fighting tomato has been named the top development in food biotechnology in 2002, according to a Roper survey of 1,000 randomly selected American adults.

When asked which publicly reported development in food biotechnology during 2002 was considered most valuable, two-thirds of respondents selected a research program that is enhancing tomatoes with a higher quantity of lycopene, an antioxidant believed to help fight cancer. The tomato is currently undergoing field tests.

Other top developments from more than 20 achievements by government and academic institutions include: sweet potatoes that can ward off a devastating plant virus; bananas and potatoes that contain a vaccine for a human virus associated with cervical cancer; produce that can stay fresh longer; and field crops that can thrive in extreme climates.

"It is these types of advances through biotechnology that can make our foods more functional and truly benefit the healthfulness of people over the long-term," said Mary Lee Chin, a registered dietitian who is a nationally recognized expert on nutrition trends and significant health and food issues. "As our society struggles with a growing range of health and nutritional issues, biotechnology is a tool that can help us grow foods that are better for our health."

Chin said food biotechnology is hitting its stride after 20 years of development and six years of commercially planted varieties that first emphasized managing pests, such as insects and weeds.

"This year's top advances in biotechnology represent a shift in the focus of plant biotechnology beyond pest management," Chin said. "More and more, biotechnology is moving toward products that will offer direct benefits to consumers, such as improved nutrient profiles and enhanced tastes."

After ranking the top developments in food biotechnology, six of every 10 respondents said they support the use of biotechnology in agriculture, while two out of every 10 were neutral and two out of every 10 expressed opposition. The study is considered to have a margin of error of plus or minus three percentage points at the 95 percent level of confidence.

The top five developments

#1 Cancer-fighting tomatoes. (65% of respondents ranked as "valuable") Field tests currently are underway for a new cancer-fighting tomato variety, which has been under development for a decade by Purdue University and the U.S. Department of Agriculture's Agricultural Research Service. The new variety offers more than three times the amount of the antioxidant lycopene compared to conventional varieties. Lycopene is known to trap harmful molecules that damage human body tissue and could lower the risk of breast and prostate cancers, as well as coronary heart disease. The development was discovered when attempting to lengthen the shelf life of tomatoes.

#2 Virus-resistant sweet potatoes. (61% ranked as "valuable") A new sweet potato variety has built-in resistance to a devastating virus that consumes more than three-fourths of the annual harvest. Scientists at the International Service for the Acquisition of Agri-Biotech Applications' AfriCenter in Nairobi, Kenya, the Kenya Agricultural Research Institute and other research institutions developed the improved sweet potato, a staple in many African countries. It is being field tested and likely will be commercially available in a few years to help in the fight against global hunger.

#3 Banana and potato vaccines. (56% ranked as "valuable") Bananas and potatoes have been developed that contain a vaccine for Human Papillomavirus (HPV), one of the most prevalent sexually transmitted diseases and the cause of almost all cervical cancer in women. Researchers with the University of Rochester have tested varieties equipped with the vaccine and work is now entering the third stage of clinical evaluation.

#4 Fresher produce. (54% ranked as "valuable") A gene that produces a plant hormone that counteracts aging and keeps fruits and vegetables fresh longer was recently discovered at the University of Leeds in the United Kingdom. Researchers currently are investing practical applications for the commercial food marketplace that would help lengthen the shelf life of fruits and vegetables and ensure they reach consumers.

#5 Hardier crops. (52% ranked as "valuable") Hardier varieties that would allow crops to flourish in extreme climates are being developed at the University of Sheffield in the United Kingdom. Researchers there have enhanced a thale cress plant, an herb from the mustard family, to have a higher tolerance to heat and light stress. This research translates into an opportunity to develop plants that could grow in extreme climates. Currently, this research is being examined for use in plants such as maize (corn), potatoes and other staple crops that are often grown for survival in the arid developing world.

The Council for Biotechnology Information commissioned the Roper survey to gauge consumer interest in new biotechnology developments. The organization provides science-based information about how biotechnology is providing more and better food while protecting the environment. To learn more about biotechnology and agriculture, visit the Council for Biotechnology Information's Web site at http://www.whybiotech.com/ or call (202) 467-6565.

Mera Pharmaceuticals Signs Technical Services Agreement With Chinese Joint Venture

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Mera Pharmaceuticals, Inc (OTC Bulletin Board: MRPI) announced today that it has signed a Technical Services Agreement (TSA) to support the design, construction and operation of a large scale, GMP certified microalgae cultivation and processing facility on Hainan Island, China. The facility is being built by Hainan Sunshine Marine Bioengineering Co., Ltd. ("HSMBCo"), a Chinese Joint Venture Company. The first phase of the facility is anticipated to cost approximately $20,000,000 and is expected to commence operation late in the third quarter of 2003. The first phase of the Hainan facility will be 32 times larger than Mera's present facility in Kona, Hawaii. In addition, the plant has been planned for expansion to 128 times the size of the Kona facility.

HSMBCo will pay Mera approximately $1 million under the TSA over the next 12 months. It is anticipated that Mera will also obtain significant revenues over that period from the sale of proprietary equipment for use at the facility. Additional contracts are anticipate to be signed with regard to services and equipment sales after the first phase of the facility is in operation.

Richard D. Propper, MD, Mera's chairman and chief executive officer, finalized the TSA agreement during his trip to China last week. He commented on his return that "The completion of this agreement represents another major step forward for Mera. First and foremost, it assures that we will have the production capacity available to meet the rapid increase in retailer demand that we are experiencing for our first product, the AstaFactor(R). In addition, by concluding this agreement, HSMBCo signified its commitment to distribute the AstaFactor(R) in China, where it projects sales of several million bottles of the AstaFactor(R) annually. Mera will receive a royalty on each of those bottles sold in China. Mera expects an annual multi-million dollar income stream from these Chinese sales of the AstaFactor(R), which will be a meaningful addition to revenues from our growing domestic sales.

"The development of the Hainan facility is an integral part of Mera's intermediate term strategic plan. By shifting cultivation and processing to Hainan, we are able to devote our resources at the Kona production facility to research and development for the next generation of our pharmaceutical and nutraceutical products, accelerating their development and introduction. By increasing the number of highly skilled positions based in Hawaii, Mera will increase the advantages that Mera enjoys under Hawaiian tax law."

Mera Pharmaceuticals, Inc., based in Kona, Hawaii, is a drug discovery and nutraceutical company with a focus on identifying and producing valuable products from the rich, untapped resource of microbial aquatic plants. Long recognized for their potential medical and nutritional value, these plants have been largely ignored because of the extreme difficulty of growing them at commercial scale. Mera has overcome that obstacle through application of its patented photobioreactor technology, which enables Mera to produce a large number of algal species at scale reliably, efficiently and at high quality. Mera's first nutraceutical product, the AstaFactor(R), is a concentrated source of natural astaxanthin, a key nutritional component of wild salmon. Astaxanthin is an extremely powerful antioxidant and a highly effective anti- inflammatory.

This press release contains forward-looking statements characterized by the use of words such as "believe," "expect," "anticipate," "feel" and similar expressions. Actual results might differ materially from those projected in, expressed in or implied by the forward-looking statements. The kinds of risks and uncertainties that could affect the future operating results of Mera include, without limitation: (i) the ability to attract new business for its existing products; (ii) the ability to identify new products and bring them to market; (iii) the ability to identify promising pharmaceutical candidates and, if they are identified, the ability to have them successfully complete the clinical trial process; (iv) the sensitivity of Mera to general economic conditions; (v) the inability to attract the additional investment needed to plans regarding the drug discovery and development business. Additional information concerning risk factors that could cause actual results to differ materially from those described in forward looking statements can be found in Mera's SEC filings, including its Annual Report on Form 10-KSB and other periodic reports that it files under the Securities Exchange Act of 1934, as amended.

First GCP(TM) Study Published In Peer-Reviewed Scientific Journal

RYE, NY, November 12, 2002 -- Dr. Aaron Katz's study titled "Regression of Prostate Cancer Following Administration of Genistein Combined Polysaccharide (GCP(TM)), A Nutritional Supplement: A Case Report," was published in the September edition of The Journal of Alternative and Complementary Medicine. Dr. Katz is the director of the Center for Holistic Urology at Columbia Presbyterian Medical Center and medical director for the U.S. GCP Research Association.

"Pre-clinical and clinical studies on GCP are very encouraging for our prostate cancer patients. The use of GCP is associated with cell death in the gland," stated Aaron E. Katz, MD. "In addition, we see significant regression of prostate cancer in several patients who were taking GCP after radical surgery. GCP can increase the PSA doubling time."

This published study reports on a case of a patient with a biopsy proven prostate cancer showing clinical and pathologic evidence of regression following administration of GCP. The patient was enrolled in an Institutional Review Board (IRB)-approved protocol and received GCP for six weeks prior to radical prostatectomy.

The patient's prostate-specific antigen (PSA) decreased from an initial value of 19.7 to 4.2 ng/mL after 44 days of low-dose GCP. No cancer was identified in the radical prostatectomy specimen and no side effects were observed in this patient. This case study suggests that GCP, which has shown potent inhibitory effects against cancer in vitro, may have some potential activity in the treatment and prevention of prostate cancer.

GCP(TM) is a nutritional supplement, manufactured in Japan, that is composed of genistein and polysaccharide obtained from basidiomycetes that grows in a variety of mushrooms, generally recognized for its anti-angiogenesis effects. GCP is well tolerated by the body with no known serious side effects and is highly bioavailable for use by the body. This study is the first GCP study to be accepted for publication in a peer-reviewed scientific journal.

The GCP Research Association, http://www.GCPresearch.com, serves as a catalyst to encourage more studies in North America as well as patient education about the benefits of this nutritional supplement.

Since 1994, over 350 medical doctors and researchers gather in Sapporo, Japan, for the annual International AHCC® and GCP(TM) Research Association Symposium. Past topics include cancer tumor reduction, hepatitis B and C treatment, liver injuries and post-operative immune system enhancement.

For more information on Genistein Combined Polysaccharide (GCP(TM)), visit the research Web site at http://www.GCPresearch.com or call 914.251.0255. If you are interested in receiving a copy of the full text edition, contact Tiia Sumera at 801.538.0777 ext.112 or [email protected].

# # #

Flaxseed shows promise against prostate cancer

12/11/02 - A diet rich in flaxseed seems to reduce the size, aggressiveness and severity of tumours in mice that have been genetically engineered to develop prostate cancer, according to new research from Duke University Medical Center in the US. And in 3 per cent of the mice, the flaxseed diet kept them from getting the disease at all, report the researchers.

"We are cautiously optimistic about these findings," said Wendy Demark-Wahnefried, associate professor at the division of urology and senior author of the study. "The amount of flaxseed given to each mouse was 5 per cent of its total food intake, which would be a very difficult amount for humans to eat, but it does signal that we are on the right track and need to continue research in this area."

According to Demark-Wahnefried, planned clinical trials must be completed before it can be concluded that dietary flaxseed protects against prostate cancer in humans.

Clinical studies by other researchers have suggested that dietary fibre reduces cancer risk, and omega-3 fatty acids also have shown a protective benefit against cancer. Flaxseed, which is high in fibre, is the richest plant source of omega-3 fatty acids. It is also a source of lignan, a specific family of fibre-related compounds that appear to play a role in influencing both oestrogen and testosterone metabolism. Since testosterone may be important in the progression of prostate cancer, lignan could help inhibit the growth and development of the disease.

In the Duke study, 135 mice genetically engineered to develop prostate cancer were divided into a control group and an experimental group. The experimental group received a regular mouse diet, but 5 per cent of the diet was in the form of flaxseed. Half of the mice in both groups were fed their respective diets for 20 weeks and the remainder for 30 weeks. At the 20- and 30-week end points, the mice were autopsied to check for tumour growth and progression of the disease to other organs.

"Tumours in the untreated control group were twice the size of tumours in the flaxseed group," said Dr Xu Lin, research associate, division of urology and lead author of the study. "The tumours were also less aggressive in the flaxseed group, and two of the mice in the flaxseed group did not develop prostate cancer at all. The rates of apoptosis (tumor cell death) were also higher in the flaxseed group. And while it was not statistically significant, the flaxseed group had fewer rates of the cancer spreading to other organs. "
While the results are promising, the researchers say they are not surprising. The study is the third in a series by the Duke Medical Center researchers to show the benefits of flaxseed in reducing the growth and development of prostate cancer.

The first study, published in July 2001 in Urology, demonstrated that a low-fat diet supplemented with flaxseed was associated with slower tumour growth. In this pilot study, 25 men with prostate cancer began adding ground flaxseed to their diets for 34 days. At the end of the study, the men saw a drop in testosterone levels and a trend toward lower prostate specific antigen (PSA) levels, a marker for prostate cancer. The diet also was tolerated well and gave the authors hope for this dietary intervention.

The second study, published in the November-December 2001 issue of Anticancer Research, examined the effect lignans have on prostate cancer cell lines. This study showed that flaxseed-derived lignans inhibited the growth of three distinct human prostate cancer cell lines through hormonally dependent and independent mechanisms.

"So far we have observed the suppression of prostate cancer in humans, mice and at the cellular level," said Lin. "It's not a fluke or a coincidence. It's an encouraging line of research."

Demark-Wahnefried added: "Our results are encouraging. However, before we can truly state that flaxseed is beneficial in humans, larger well-controlled trials are needed. The National Cancer Institute has provided us with the support to conduct a randomised clinical trial in 160 men with prostate cancer that will examine whether a low-fat diet, flaxseed supplementation or a combination of low-fat diet and flaxseed supplementation will be most effective in stopping prostate cancer cells from dividing. That trial is currently under way." The latest research is published in the November 2002 issue of Urology, and was sponsored by the National Institute on Aging, the National Cancer Institute and the Committee for Urologic Research Education and Development at Duke University Medical Center.

Integrated Health Technologies, Inc. Reports First Quarter Financial Results

HILLSIDE, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Integrated Health Technologies, Inc. (BULLETIN BOARD: IHTC.OB) today announced its financial results for the first quarter ended September 30, 2002.

First quarter revenues decreased approximately 7% to $4,848,190 from $5,084,994 for the same period a year ago. Net operating income for the quarter was $186,510 or $.03 per share on 7,170,783 shares outstanding compared to operating income of $35,616 or $.01 per share on 6,228,720 shares outstanding for the comparable quarter of last year.

"We are pleased with the continued improvement in profits and are encouraged that this trend will continue," commented Seymour Flug, President and Chief Executive Officer of Integrated Health Technologies, Inc.

Integrated Health Technologies, Inc. is a unique grouping of companies presently serving the diversified needs of the nutraceutical industry: Manhattan Drug Company, Inc. provides contract manufacturing, IHT Health Products, Inc. provides raw material sourcing and Integrated Health Ideas, Inc. provides new product development and technical services.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

OptiPure® Launches New High Potency Stable Feverfew Powder

Los Angeles, CA – OptiPure® announces the launch of PharmaFew, the first high potency, stable feverfew powder. Feverfew assists in preventing and lessening migraines, as well as alleviating joint pain and allergies. The main active ingredient in feverfew is parthenolide. OptiPure® PharmaFew contains up to 4% stable parthenolide while other feverfew extracts have reached only a 2% unstable parthenolide content. PharmaFew is uniquely extracted and dried from the feverfew herb, with a boosted potency from 0.9% active ingredient up to 4%. Pharmafew’s high potency can be taken in smaller doses or formulated with other ingredients. Pharmafew is a kosher extract and is the result of 4 years of research and 3 years of stability testing in accelerated shelf-life tests.

Twinlab Corporation to Discontinue Sale of Products Containing Ephedra

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Nov. 11, 2002--Twinlab Corporation (Nasdaq:TWLB), a leading manufacturer and marketer of high quality, science-based, nutritional supplements, announced today that it will discontinue selling ephedra-containing supplements effective March 31, 2003 and will focus its efforts on meeting consumer's needs with clinically proven, non-ephedra products in the diet and energy category.

"We were recently granted a U.S. patent on one of our weight loss formulations which puts us in a unique position to respond to the growing consumer demand for efficacious ephedra-free products," stated Ross Blechman, Twinlab's Chairman, President and Chief Executive Officer. "We are excited to move forward aggressively in the ephedra-free diet and energy category using our technological expertise to answer consumers' weight loss needs."

Twinlab has launched a line of patented and clinically tested ephedra-free products under its leading national brands, including Ripped Fuel, Diet Fuel and Metabolift. In a recent clinical study, the Company's ephedra-free product formula illustrated significant weight loss results and an average 13% body fat decrease in study participants. The brands will be supported with an aggressive advertising and promotion plan to generate significant consumer awareness and trial.

"We believe this is a sound business decision in the current climate of escalating insurance costs, and regulatory uncertainties, and are confident that our long history of providing safe and effective products, combined with our superior product technology, will make this a positive move for the Company, its customers and consumers," added CEO Blechman.

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: (i) the impact of competitive products; (ii) changes in law and regulations; (iii) adequacy and availability of insurance coverage; (iv) limitations on future financing; (v) increases in the cost of borrowings and unavailability of debt or equity capital; (vi) the effect of adverse publicity regarding nutritional supplements; (vii) uncertainties relating to acquisitions; (viii) the inability of the Company to gain and/or hold market share; (ix) exposure to and expense of resolving and defending product liability claims and other litigation; (x) consumer acceptance of the Company's products; (xi) managing and maintaining growth; (xii) customer demands; (xiii) the inability to integrate and consolidate its manufacturing and distribution facilities and achieve cost savings and operational efficiencies; (xiv) dependence on individual products; (xv) dependence on individual customers, (xvi) market and industry conditions including pricing, demand for products, levels of trade inventories and raw materials availability, (xvii) the success of product development and new product introductions into the marketplace including the Company's line of ephedra-free products; (xviii) lack of available product liability insurance for ephedra-containing products; (xix) slow or negative growth in the nutritional supplement industry; (xx) the departure of key members of management; (xxi) the absence of clinical trials for many of the Company's products; (xxii) the ability of the Company to efficiently manufacture its products; as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

Additional Twinlab information is available on the World Wide Web at: http://www.twinlab.com.

Californians Embrace Traditional Latin Beverage

CA Study Finds 93% of non-Latinos 'Likely to Prepare' Licuados at Home

BERKELEY, Calif., Nov. 11 /PRNewswire/ -- Today the California Milk Processor Board (CMPB) released the results of its eight-city study designed to find out how non-Latinos feel about Licuados. Pronounced lee-kwa-dohs, these traditional Latin drinks are made in a blender with cold milk, fruit, and a variety of other ingredients. They are enjoyed both at home, and at sidewalk "Licuado Bars," across much of Mexico, the Spanish-speaking Americas and the Caribbean.

Beginning in August, the CMPB held in-home Licuado research with more than 500 non-Latino Californians (between the ages of 25 and 45) in eight cities across the state, including: Fresno, Los Angeles, Oakland, Orange County, Sacramento, San Diego, San Francisco and Van Nuys.

"Our objective was to determine if Licuados could 'cross-over' into mainstream cuisine," says Jeff Manning, executive Director of the CMPB. "Based on these results, Licuados could become the next burrito or sangria."

"I'd never heard of Licuados before now," said Angela Gianulias, a survey participant from Sacramento. "They struck me as a wonderful, healthy drink, and a great way to jumpstart the day."
Some research highlights:

-- Over 90% liked the concept of Licuados.
-- 93% liked the taste of Licuados.
-- Nearly 70% listed freshness as the most important characteristic.
-- 74% thought Licuados made great snacks.
-- Nearly half (52%) thought Licuados made a good meal replacement.
-- Surprisingly, even though 40% of those asked thought Licuados were
"time-consuming" to prepare, 93% still said they were likely to make
them at home.

"Californians are obsessed with time," said Manning. "The reality is that you can whip up a fresh, great tasting Licuado -- and clean the blender -- in just minutes."

As part of the in-home research, the CMPB sampled 26 new and traditional Licuado recipes, many created by one of Southern California's leading Latin chefs and restaurant owners, Toribio Prado. Many of these are available on http://www.gotmilk.com and will soon be found on restaurant menus and at Licuado bars throughout California. See "Licuado Futures."

To obtain a copy of the study results, set up an interview or get more information on Licuados -- please contact, Paola Risso at 310-385-1697.

About the CMPB
The California Milk Processor Board was established in 1993 to make milk more competitive and increase milk consumption in California. GOT MILK? is a registered trademark and has been licensed nationally since 1995. The CMPB launched a Spanish language marketing campaign in 1994. The CMPB is funded by all California milk processors and administered by the California Department of Food and Agriculture.

Licuado Futures!
Milk Board's Predications for the next 18 months

-- Licuado bars will spring up around California and the country.
-- Licuados will show up on the menus of major restaurant and smoothie
chains.
-- Licuados will become the focus of co-branding, e.g., Del Monte
Bananas, Nestle Morsels.
-- Blender manufacturers will add fuel to the Licuado craze.
-- Licuados will become a household word (and much beloved beverage).

Winslow Management Appoints Patsky Portfolio Manager

BOSTON, Mass., Nov. 11, 2002 – Winslow Management Company, a leading green investing firm, announced today that Matthew W. Patsky, CFA has been named to the position of Portfolio Manager.

In his new position, he will work with President Jackson W. Robinson to make the firm’s portfolio investment decisions.

Before joining Winslow, Patsky, a resident of Boston, served as Director of Equity Research for Boston-based Adams, Harkness & Hill, an emerging-growth investment bank. Winslow merged with Adams, Harkness & Hill in 1999. Directing the firm’s Research Department, he supervised 21 research analysts focused on emerging growth technology, healthcare and consumer companies.

As an analyst, he was responsible for developing the Healthy Living® investment theme and selecting the initial group of companies, now recognized by investment professionals as an important sector. He also wrote many industry reports, including the first report on socially responsible investing ever published by an investment bank. Before joining Adams, Harkness & Hill, he was an analyst for Robertson Stephens, focusing on natural foods, beverages and nutrition. He started his career as a technology analyst at Lehman Brothers, before moving into the emerging-growth consumer sector.

He earned his bachelor’s degree from Rensselaer Polytechnic Institute (RPI) in Troy, N.Y. and is a chartered financial analyst (CFA). He is a member of the Association for Investment Management and Research (AIMR) and the Social Venture Network.

* * * * *

Winslow Management Company (www.winslowgreen.com) seeks to invest in high growth and environmentally effective companies. From its inception in 1984, Winslow has been investing the assets of high-net-worth individuals, non-profit institutions, and pension funds in growth companies that are environmentally sensitive. Its products and services include: The Winslow Green Growth Fund*, an equity growth fund open to individual and institutional investors; The Green Century Balanced Fund**, to which it is the subadviser; individual portfolio management for high-net-worth individuals and institutions, and a hedge fund that is open to qualified clients. Based in Boston, Winslow manages assets totaling approximately $90 million as of Sept. 30, 2002.

*Mutual funds are subject to market risk, which causes their value to fluctuate. The Winslow Green Growth Fund invests in small and medium size companies which pose greater risks than those associated with larger, more established companies. Forum Fund Services, LLC is the distributor for the Winslow Green Growth Fund. For additional information about this Fund, including fees and expenses, request a prospectus by calling 888-314-9049. Please read the prospectus carefully before investing.

** For a free prospectus with more complete information about the Green Century Balanced Fund, including fees and expenses, please call 1-800-93-GREEN or visit www.greencentury.com. Please read the prospectus carefully before you invest or send money.

The Green Century Balanced Fund is distributed by UMB Distribution Services, LLC 11/02.

#####

Leigh Ann Steele
Winslow Management Company
617-371-3791
[email protected]

David P. Kowal, APR
Kowal Communications, Inc.
508-393-7023
[email protected]